- Home
- NEPH vs IOTR Comparison
NEPH vs IOTR Comparison
Compare NEPH & IOTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEPH
- IOTR
- Stock Information
- Founded
- NEPH 1997
- IOTR 2019
- Country
- NEPH United States
- IOTR Singapore
- Employees
- NEPH N/A
- IOTR N/A
- Industry
- NEPH Medical/Dental Instruments
- IOTR
- Sector
- NEPH Health Care
- IOTR
- Exchange
- NEPH Nasdaq
- IOTR NYSE
- Market Cap
- NEPH 36.1M
- IOTR 29.5M
- IPO Year
- NEPH 2004
- IOTR 2025
- Fundamental
- Price
- NEPH $4.24
- IOTR $0.41
- Analyst Decision
- NEPH Buy
- IOTR
- Analyst Count
- NEPH 1
- IOTR 0
- Target Price
- NEPH $5.00
- IOTR N/A
- AVG Volume (30 Days)
- NEPH 65.7K
- IOTR 465.4K
- Earning Date
- NEPH 08-07-2025
- IOTR 01-01-0001
- Dividend Yield
- NEPH N/A
- IOTR N/A
- EPS Growth
- NEPH N/A
- IOTR N/A
- EPS
- NEPH 0.08
- IOTR N/A
- Revenue
- NEPH $15,517,000.00
- IOTR $9,578,336.00
- Revenue This Year
- NEPH $17.06
- IOTR N/A
- Revenue Next Year
- NEPH $12.20
- IOTR N/A
- P/E Ratio
- NEPH $55.19
- IOTR N/A
- Revenue Growth
- NEPH 10.34
- IOTR 13.93
- 52 Week Low
- NEPH $1.36
- IOTR $0.31
- 52 Week High
- NEPH $5.00
- IOTR $5.98
- Technical
- Relative Strength Index (RSI)
- NEPH 61.33
- IOTR N/A
- Support Level
- NEPH $4.00
- IOTR N/A
- Resistance Level
- NEPH $5.00
- IOTR N/A
- Average True Range (ATR)
- NEPH 0.49
- IOTR 0.00
- MACD
- NEPH 0.01
- IOTR 0.00
- Stochastic Oscillator
- NEPH 55.56
- IOTR 0.00
About NEPH Nephros Inc.
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of its revenue from product sales and a small amount from royalty revenue and other revenues.